Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and ...

Larry Pitcher is the CEO of Kincell Bio. He brings over 20 years of leadership experience in biopharmaceutical manufacturing, ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

At the 2024 annual meeting of the International Society for Cell & Gene Therapy (ISCT) in Vancouver, Canada, Hélio Tomás, PhD, senior research associate at the Instituto de Biologia Experimental e ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...